The optimal morning

Evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: A 24-week multi-centre prospective, randomized controlled, open-labelled clinical study

C. H. Jung, J. Y. Park, J. H. Cho, K. H. Yoon, H. K. Yang, Y. H. Lee, B. S. Cha, byungwan lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: Biphasic insulin analogues are widely used in patients with Type 2 diabetes mellitus suboptimally controlled on oral anti-diabetic drugs. Several topics in this area remain controversial, including how to divide the daily dose of biphasic insulin analogue. We aimed to determine the optimal dosing ratio of twice-daily biphasic insulin analogue and to compare the glycaemic efficacy among groups of patients using different initial dosing ratios of biphasic insulin analogue. Methods: A total of 100 poorly controlled insulin-naive subjects with Type 2 diabetes [HbA1c ≥ 58 mmol/mol, (7.5%)] on oral anti-diabetic drugs were randomized into three groups according to initial morning:evening dosing ratio (group I, 50:50; group II, 55:45; group III, 60:40) of twice-daily biphasic insulin analogue (biphasic insulin aspart 70/30, biphasic insulin aspart 30). The primary outcome measure was the difference in pre-breakfast to pre-dinner dose ratio at the end of the study. Results: Twice-daily biphasic insulin analogue showed a significant improvement in glycaemic control [HbA1c from 70 mmol/mol (8.6%) to 60 mmol/mol (7.6%)] after 24 weeks regardless of the initial dose ratio given. Despite the similar efficacy and safety profiles among three groups, morning dose was significantly increased (from 50:50 to 55:45-60:40) in group I after 24 weeks. However, there was no significant change in splitting ratio in groups II and III (with higher morning dose) over the 24-week treatment period. Conclusions: These results indicate that initiating twice-daily biphasic insulin analogue on regimens with a higher dose before breakfast than before dinner (i.e. ratio approximately 55:45 to 60:40) might be more appropriate in Korean subjects with Type 2 diabetes.

Original languageEnglish
Pages (from-to)68-75
Number of pages8
JournalDiabetic Medicine
Volume31
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Biphasic Insulins
Type 2 Diabetes Mellitus
Breakfast
Meals
Clinical Studies
Pharmaceutical Preparations
Outcome Assessment (Health Care)
Insulin
Safety

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{01e79b3b252a402c90259e998d3fabde,
title = "The optimal morning: Evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: A 24-week multi-centre prospective, randomized controlled, open-labelled clinical study",
abstract = "Aims: Biphasic insulin analogues are widely used in patients with Type 2 diabetes mellitus suboptimally controlled on oral anti-diabetic drugs. Several topics in this area remain controversial, including how to divide the daily dose of biphasic insulin analogue. We aimed to determine the optimal dosing ratio of twice-daily biphasic insulin analogue and to compare the glycaemic efficacy among groups of patients using different initial dosing ratios of biphasic insulin analogue. Methods: A total of 100 poorly controlled insulin-naive subjects with Type 2 diabetes [HbA1c ≥ 58 mmol/mol, (7.5{\%})] on oral anti-diabetic drugs were randomized into three groups according to initial morning:evening dosing ratio (group I, 50:50; group II, 55:45; group III, 60:40) of twice-daily biphasic insulin analogue (biphasic insulin aspart 70/30, biphasic insulin aspart 30). The primary outcome measure was the difference in pre-breakfast to pre-dinner dose ratio at the end of the study. Results: Twice-daily biphasic insulin analogue showed a significant improvement in glycaemic control [HbA1c from 70 mmol/mol (8.6{\%}) to 60 mmol/mol (7.6{\%})] after 24 weeks regardless of the initial dose ratio given. Despite the similar efficacy and safety profiles among three groups, morning dose was significantly increased (from 50:50 to 55:45-60:40) in group I after 24 weeks. However, there was no significant change in splitting ratio in groups II and III (with higher morning dose) over the 24-week treatment period. Conclusions: These results indicate that initiating twice-daily biphasic insulin analogue on regimens with a higher dose before breakfast than before dinner (i.e. ratio approximately 55:45 to 60:40) might be more appropriate in Korean subjects with Type 2 diabetes.",
author = "Jung, {C. H.} and Park, {J. Y.} and Cho, {J. H.} and Yoon, {K. H.} and Yang, {H. K.} and Lee, {Y. H.} and Cha, {B. S.} and byungwan lee",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/dme.12322",
language = "English",
volume = "31",
pages = "68--75",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "1",

}

The optimal morning : Evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: A 24-week multi-centre prospective, randomized controlled, open-labelled clinical study. / Jung, C. H.; Park, J. Y.; Cho, J. H.; Yoon, K. H.; Yang, H. K.; Lee, Y. H.; Cha, B. S.; lee, byungwan.

In: Diabetic Medicine, Vol. 31, No. 1, 01.01.2014, p. 68-75.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The optimal morning

T2 - Evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: A 24-week multi-centre prospective, randomized controlled, open-labelled clinical study

AU - Jung, C. H.

AU - Park, J. Y.

AU - Cho, J. H.

AU - Yoon, K. H.

AU - Yang, H. K.

AU - Lee, Y. H.

AU - Cha, B. S.

AU - lee, byungwan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aims: Biphasic insulin analogues are widely used in patients with Type 2 diabetes mellitus suboptimally controlled on oral anti-diabetic drugs. Several topics in this area remain controversial, including how to divide the daily dose of biphasic insulin analogue. We aimed to determine the optimal dosing ratio of twice-daily biphasic insulin analogue and to compare the glycaemic efficacy among groups of patients using different initial dosing ratios of biphasic insulin analogue. Methods: A total of 100 poorly controlled insulin-naive subjects with Type 2 diabetes [HbA1c ≥ 58 mmol/mol, (7.5%)] on oral anti-diabetic drugs were randomized into three groups according to initial morning:evening dosing ratio (group I, 50:50; group II, 55:45; group III, 60:40) of twice-daily biphasic insulin analogue (biphasic insulin aspart 70/30, biphasic insulin aspart 30). The primary outcome measure was the difference in pre-breakfast to pre-dinner dose ratio at the end of the study. Results: Twice-daily biphasic insulin analogue showed a significant improvement in glycaemic control [HbA1c from 70 mmol/mol (8.6%) to 60 mmol/mol (7.6%)] after 24 weeks regardless of the initial dose ratio given. Despite the similar efficacy and safety profiles among three groups, morning dose was significantly increased (from 50:50 to 55:45-60:40) in group I after 24 weeks. However, there was no significant change in splitting ratio in groups II and III (with higher morning dose) over the 24-week treatment period. Conclusions: These results indicate that initiating twice-daily biphasic insulin analogue on regimens with a higher dose before breakfast than before dinner (i.e. ratio approximately 55:45 to 60:40) might be more appropriate in Korean subjects with Type 2 diabetes.

AB - Aims: Biphasic insulin analogues are widely used in patients with Type 2 diabetes mellitus suboptimally controlled on oral anti-diabetic drugs. Several topics in this area remain controversial, including how to divide the daily dose of biphasic insulin analogue. We aimed to determine the optimal dosing ratio of twice-daily biphasic insulin analogue and to compare the glycaemic efficacy among groups of patients using different initial dosing ratios of biphasic insulin analogue. Methods: A total of 100 poorly controlled insulin-naive subjects with Type 2 diabetes [HbA1c ≥ 58 mmol/mol, (7.5%)] on oral anti-diabetic drugs were randomized into three groups according to initial morning:evening dosing ratio (group I, 50:50; group II, 55:45; group III, 60:40) of twice-daily biphasic insulin analogue (biphasic insulin aspart 70/30, biphasic insulin aspart 30). The primary outcome measure was the difference in pre-breakfast to pre-dinner dose ratio at the end of the study. Results: Twice-daily biphasic insulin analogue showed a significant improvement in glycaemic control [HbA1c from 70 mmol/mol (8.6%) to 60 mmol/mol (7.6%)] after 24 weeks regardless of the initial dose ratio given. Despite the similar efficacy and safety profiles among three groups, morning dose was significantly increased (from 50:50 to 55:45-60:40) in group I after 24 weeks. However, there was no significant change in splitting ratio in groups II and III (with higher morning dose) over the 24-week treatment period. Conclusions: These results indicate that initiating twice-daily biphasic insulin analogue on regimens with a higher dose before breakfast than before dinner (i.e. ratio approximately 55:45 to 60:40) might be more appropriate in Korean subjects with Type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84890191111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890191111&partnerID=8YFLogxK

U2 - 10.1111/dme.12322

DO - 10.1111/dme.12322

M3 - Article

VL - 31

SP - 68

EP - 75

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 1

ER -